

BIOTECHNOLOGY

LAW, BUSINESS, AND REGULATION

MICHAEL J. MALINOWSKI

FOLEY, HOAG & ELIOT LLP



ASPEN LAW & BUSINESS

CONTENTS

<i>List of Appendices</i>	<i>xvii</i>
<i>About the Authors</i>	<i>xix</i>
<i>About the Contributors</i>	<i>xxi</i>
<i>Foreword</i>	<i>xxvii</i>
<i>Preface</i>	<i>xxxi</i>
<i>Acknowledgments</i>	<i>xxxiii</i>
<i>Industry Overview</i>	<i>xxxv</i>

Chapter 1

ACADEMIC RESEARCH—LABORATORY POLICIES AND PROCEDURES

§ 1.01	Introduction	1-3
§ 1.02	Basic Research Alliance Models	1-7
§ 1.03	Overview of Research Agreements	1-12
§ 1.04	The Parameters of Biotech Research Agreements ..	1-14
§ 1.05	Fundamental Administrative Measures	1-15
	[A] Centralization of Technology Transfer	1-18
	[1] A Deliberative, Long-Term Strategy ...	1-20
	[a] Appreciation for the Realities of Health Care Finance	1-22
	[b] Careful Deliberation of Partnering Options	1-24
	[c] Appreciation for Overall Business Administration	1-24
	[d] Preservation of Property Interests	1-25
	[2] Institutional Judgment	1-28
	[3] Oversight	1-29

	[4] Technology Transfer Case Study: Howard Hughes Medical Institute	1-35
[B]	Policies That Address Property Rights to Biological Source Materials	1-36
[C]	Participation Agreements and Employment Policies That Preserve Property Interests	1-45
	[1] Employment Practices	1-46.1
	[2] Pressing Employment Issues in Basic Biotechnology Research	1-48
	[a] Conflicts of Interest	1-48
	[b] Ownership of Research	1-49
	[c] Employment Policy Case Study: Howard Hughes Medical Institute	1-59
	[d] Publication and Recording Procedures	1-60
[D]	Awareness of and Compliance with Basic Research Regulatory Schemes	1-66
	[1] Regulation of Basic Biotechnology Research in the U.S.	1-73
	[2] Regulation of Basic Biotechnology Research in the EU	1-77
	[a] European Union Regulation	1-78
	[b] Member State Regulation	1-80

Chapter 2

	PATENT PROTECTION	2-1
§ 2.01	Introduction	2-3
§ 2.02	Legal Standards: United States (U.S.)	2-6
	[A] Essential Elements of a Patent Application	2-6
	[1] Statutory Subject Matter	2-6
	[2] Written Description	2-8
	[3] Enabling Disclosure	2-9
	[4] Utility Requirement	2-13
	[5] Novelty Requirement	2-15
	[6] Nonobviousness Requirement	2-17
[B]	Patent Claim Construction and Literal Infringement	2-18
[C]	Infringement Under the Doctrine of Equivalents	2-21

CONTENTS

	[D] Infringement of Process Patents	2-22
§ 2.03	Legal Standards: European Union (EU)	2-25
	[A] Substantive Law	2-26
	[B] Procedure: EPO, PCT, and PLT	2-32
	[1] European Patent Office	2-32
	[2] Patent Cooperation Treaty	2-35
	[3] Patent Law Treaty	2-37
§ 2.04	U.S.-EU Comparative Analysis of Intellectual Property Patent Protection in Biotechnology	2-38
§ 2.05	Patent Prosecution in the U.S.	2-41
§ 2.06	Patent Enforcement and Litigation in the U.S.	2-46
§ 2.07	International Intellectual Property Framework	2-53
	[A] Paris Convention	2-57
	[B] Patent Cooperation Treaty	2-58
	[C] General Agreement on Tariffs and Trade and Trade-Related Aspects of Intellectual Property Rights	2-58
	[D] The Convention on Biological Diversity	2-60
	[E] North American Free Trade Agreement	2-64

Chapter 3

	OPTIONS FOR RAISING CAPITAL	3-1
§ 3.01	Introduction	3-3
§ 3.02	Overview of Biotech Finance Trends	3-9
	[A] Maturation of Biotech Science and the Industry	3-9
	[B] A Shift in Pharmaceutical Research and Development Toward Biotechnology	3-9
	[C] Privatization of Life Science Research and Development	3-24.8
	[D] Globalization of Investment in Biotech Research and Development	3-24.12
	[1] Venture Capital Investment	3-24.13
	[2] Corporate Partnerships	3-24.16
§ 3.03	Biotech Financing Mechanisms	3-27

Chapter 4

	VENTURE CAPITAL	4-1
§ 4.01	Introduction	4-3

§ 4.02	Seed Money/Angel Venture Capital	4-3
§ 4.03	Standard Venture Capital	4-4
§ 4.04	Private Placements	4-9
§ 4.05	The Mechanics of Venture Capital Investment	4-11
[A]	The Venture Capital Process	4-12
[1]	Identification of Potential Venture Capital	4-13
[2]	Procurement of Venture Capital Investment	4-13
[3]	Valuation	4-17
[B]	The Business Plan	4-25
[C]	The Financials	4-30.1
[D]	Negotiation of Venture Capital Investment	4-30.3
[E]	Choice of Investment Form	4-37
[1]	Preferred Stock	4-37
[2]	Convertible Notes	4-38
[3]	Warrants and Options	4-39
[4]	Tax and Other Finance Considerations	4-40
[5]	Securities Issues	4-42
[6]	Documents	4-44
[a]	The Term Sheet	4-46
[b]	The Preferred Stock Purchase Agreement	4-52
[c]	The Investor Rights Agreement ..	4-58
[d]	The Founders' Agreement	4-58
[e]	The Proprietary Information and Inventions Agreement	4-67
[f]	The Restated Certificate of Incorporation	4-68

Chapter 5

	ALLIANCE AGREEMENTS	5-1
§ 5.01	Introduction	5-3
§ 5.02	Biotech Partnering Trends	5-3
[A]	Academic and Industry Partnering	5-4
[B]	Pharma-Biotech Partnering	5-7
[C]	Biotech-Biotech Partnering	5-12.1
§ 5.03	The Fundamentals of Corporate Partnering	5-12.3
[A]	Assessing the Alliance Option	5-14

CONTENTS

[B]	Negotiating and Structuring Corporate Alliances	5-21
[C]	Documenting the Deal	5-25

Chapter 6

GRANT FUNDING FOR BASIC LIFE SCIENCE RESEARCH

		6-1
§ 6.01	Introduction	6-3
§ 6.02	Priorities and Criteria for Federal Funding	6-5
§ 6.03	Avenues for Obtaining Federal Grant Funding	6-10
§ 6.04	Non-Government Sources for U.S. Grant Funding	6-14
§ 6.05	Grant Funding in the European Union	6-19

Chapter 7

GOVERNMENT COOPERATIVE TECHNOLOGY PROGRAMS AND TAX INCENTIVES

		7-1
§ 7.01	Introduction	7-3
§ 7.02	Overview of Federal and State Cooperative Technology Programs	7-4
§ 7.03	State-U.S. Technology Programs	7-6
	[A] University-Industry Technology Centers	7-8
	[B] Government-Industry Consortia	7-9
	[C] University-Industry Research Partnerships	7-10
	[D] Equipment and Facility Access Programs	7-10
	[E] Technology Extension/Deployment	7-11
	[F] Implementation Grants	7-11
	[G] Company Financing	7-11
§ 7.04	U.S. Federal-State Cooperative Technology Programs	7-12
	[A] Tax Incentives	7-13
	[B] Project Financing	7-13
	[C] State-Sponsored Federal Outreach	7-18
	[D] Incubators	7-19
	[E] Start-up Assistance	7-19
	[F] Industrial Networks	7-20
	[G] Interactive Databases	7-20
§ 7.05	U.S. Federal Technology Programs	7-21

	[A] Federal Technology Applications Programs ..	7-21
	[B] Small Business Investment Companies	7-22
§ 7.06	Canadian and EU Tax Incentives and Technology Programs	7-23
	[A] Canadian Programs	7-23
	[B] EU Programs	7-27
§ 7.07	Compendium of U.S. Small Business/Biotechnology Programs and Contact Information	7-47
	[A] Research Sources	7-47
	[B] Selected Federal Programs	7-47
	[C] Selected State Organizations and Programs ..	7-52

Chapter 8

TECHNOLOGY TRANSFER AND DEVELOPMENT AGREEMENTS

8-1

§ 8.01	Introduction	8-3
§ 8.02	Research and Development Agreements	8-6
	[A] Background: U.S. Technology Transfer Policy	8-8
	[B] Structuring Technology Transfer Agreements	8-19
	[C] Cooperative Research and Development Agreements and Outsourcing Agreements ...	8-22
	[1] Cooperative Research and Development Agreements	8-22
	[2] Outsourcing Agreements	8-26
	[a] Outsourcing Agreement Fundamentals	8-26
	[b] Application 1: Clinical Research Agreements	8-33
	[c] Application 2: Contract Manufacturing Agreements	8-48
§ 8.03	Assignments, Licenses, and Joint Ventures	8-49
	[A] Preliminary Agreements	8-55
	[1] Mutual Nondisclosure Agreement	8-55
	[2] Nonconfidential Evaluation Agreement	8-56
	[3] Evaluation Agreement	8-56
	[4] Letter of Intent	8-57
	[B] Transaction Agreement Highlights	8-57
	[1] Confidentiality Agreements	8-58

	[2] Joint Ventures	8-59
	[3] Licensing Agreements	8-60
	[4] Supply Agreements	8-60
	[5] Purchasing and Manufacturing Agreements	8-61
§ 8.04	Drafting Agreements	8-62
	[A] Fundamental Provisions and Factors for Deliberation	8-62
	[1] Scope of the Transfer	8-62
	[2] Consideration	8-63
	[3] Responsibility for Protecting Shared Interest	8-64
	[4] Maintenance of the Parties' Relationship	8-64
	[5] Interaction with Third Parties	8-65
	[6] Other Issues	8-66
	[B] Fundamental Considerations for Transnational Transactions	8-66
	[1] Prenegotiation Considerations	8-66
	[2] Transaction Considerations	8-72
§ 8.05	Antitrust and Competition Laws	8-76
	[A] U.S. Antitrust Law	8-76
	[B] EU Competition Laws	8-81
§ 8.06	Regulation of International Technology-based Transactions	8-91
	[A] General Considerations	8-91
	[B] Guidelines and Strategies for Engaging in Indigenous Population and Species Studies ..	8-92
	[1] Resistance to Indigenous Population Studies	8-95
	[2] Guidelines and Strategies for Engaging in Indigenous Population and Species Research	8-97

Chapter 9

REGULATION OF HUMAN SUBJECTS

	RESEARCH	9-1
§ 9.01	Introduction	9-3
§ 9.02	Overview of Regulation of Human Subjects Research in the U.S. and the EU	9-5

§ 9.03	Regulatory Safeguards to Protect Human Subjects	9-19
	[A] Codification of Domestic/National Professional Standards	9-26
	[B] The Doctrine of Informed Consent in the U.S.	9-31
	[1] Disclosure Standards	9-34
	[2] Application	9-36
	[3] Waiver Under Federal Law	9-38
	[4] Implementation Mechanisms	9-39
	[C] The Doctrine of Informed Consent in the EU	9-44
§ 9.04	Comparative Considerations	9-46
	[A] Research Record-Keeping	9-54
	[B] Access to Patients	9-55
	[C] Expert Reports	9-59
	[D] Import/Export Issues	9-61
	[E] Liability	9-64
§ 9.05	Additional Considerations and Suggestions	9-66
	[A] Interacting Constructively with the FDA	9-67
	[B] Practicing Clinical Prudence	9-68
	[C] Self-Policing Against Scientific Misconduct	9-69
	[D] Anticipating Scale-up and Other Clinical Problems	9-71
§ 9.06	Summary of Clinical Trial Contract Considerations	9-75

Chapter 10

CLINICAL LABORATORY REGULATIONS

§ 10.01	Introduction	10-3
§ 10.02	Regulation of Clinical Laboratories in the U.S.	10-4
	[A] CLIA Overview	10-5
	[1] The CLIA Complexity Model and Classification Scheme	10-7
	[a] Exempt Laboratories	10-7
	[b] Certified Laboratories	10-8
	[c] CLIA Accrediting Bodies	10-10
	[2] CLIA Standards, Requirements, and Obligations	10-13
	[a] CLIA Personnel Requirements ...	10-14

	[b] Patient Test Management Under CLIA	10-14
	[c] Proficiency Testing Under CLIA	10-15
	[d] Quality Control and Assurance Under CLIA	10-16
	[3] CLIA Laboratory Specialty Standards ..	10-27
	[4] CLIA Enforcement	10-27
	[5] Due Process and Judicial Review Under CLIA	10-29
	[B] Other Federal Entities with Jurisdiction over Laboratories	10-30
	[C] Professional Organization Standards	10-30
	[D] State Regulations	10-32
	[E] Advertising Restrictions	10-36
	[F] Patient Care and Liability Issues	10-37
	[G] Billing	10-41
	[H] Fraud and Abuse	10-41
	[I] Regulation of Ancillary Products	10-41
§ 10.03	The Fundamental Rubric of the EU Regulatory Scheme	10-42
	[A] EU Standards and Regulations	10-43
	[B] Emigration of U.S. R&D to EU Clinical Laboratories	10-44
	[C] Case Study: Regulation of Clinical Laboratory Research in the UK	10-45
Chapter 11		
PRODUCT REVIEW AND APPROVAL		
		11-1
§ 11.01	Introduction	11-3
§ 11.02	Therapeutics	11-12
	[A] Review and Approval in the U.S.	11-12
	[1] CBER Classification	11-14
	[2] Clinical Process	11-17
	[3] BLAs, NDAs, and ANDAs	11-20
	[4] NEPA Requirement	11-29
	[5] FDA Reform Movement	11-31
	[B] Review and Approval in the EU	11-46
§ 11.03	Diagnostics and Devices	11-58
	[A] Review and Approval in the U.S.	11-58

	[1] Biotechnology-based Diagnostics	11-60
	[2] Reform Movement	11-61
	[B] Review and Approval in the EU	11-65
§ 11.04	Tissue Engineering, Transplant Procedures, and Gene Therapies	11-71
§ 11.05	Veterinary Products	11-80
§ 11.06	Agricultural and Environmental Products	11-85
	[A] Review and Approval in the U.S.	11-87
	[1] EPA Regulation of Pesticides	11-89
	[2] EPA Regulation of NCSs	11-97
	[3] EPA Regulation of Living Organisms ..	11-100
	[a] The 1986 Statement of Policy	11-101
	[b] The 1997 Final Rules	11-104
	[c] SNURs	11-110
	[4] USDA Regulation of Plant and Animal Products	11-111
	[a] Seeds	11-111
	[b] Plant Pests	11-112
	[c] Meat and Poultry	11-120
	[5] FDA Regulation of Food and Food Additives	11-121
	[B] Review and Approval in the EU	11-127
§ 11.07	Collaboration Between the U.S. and EU	11-131
	[A] Therapeutics and Diagnostics	11-132
	[B] Agbio and Biotech Environmental Products ..	11-136
§ 11.08	The NEPA Requirement for All New U.S. Biotech Products	11-140
<i>Afterword</i>		<i>AF-1</i>
<i>Glossary</i>		<i>G-1</i>
<i>Index</i>		<i>I-1</i>

SUMMARY OF CONTENTS

<i>Contents</i>	vii
<i>List of Appendices</i>	xvii
<i>About the Author</i>	xix
<i>About the Contributors</i>	xxi
<i>Foreword</i>	xxvii
<i>Preface</i>	xxxi
<i>Acknowledgments</i>	xxxiii
<i>Industry Overview</i>	xxxv
Chapter 1 Academic Research—Laboratory Policies and Procedures	1-1
Chapter 2 Patent Protection	2-1
Chapter 3 Options for Raising Capital	3-1
Chapter 4 Venture Capital	4-1
Chapter 5 Alliance Agreements	5-1
Chapter 6 Grant Funding for Basic Life Science Research	6-1
Chapter 7 Government Cooperative Technology Programs and Tax Incentives	7-1
Chapter 8 Technology Transfer and Development Agreements	8-1
Chapter 9 Regulation of Human Subjects Research	9-1

Chapter 10	Clinical Laboratory Regulations	10-1
Chapter 11	Product Review and Approval	11-1
<i>Afterword</i>		<i>AF-1</i>
<i>Glossary</i>		<i>G-1</i>
<i>Index</i>		<i>I-1</i>

/